Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?

Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaborowska, Magdalena, Szmit, Sebastian, Szczylik, Cezary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2012
Materias:
State of the Art Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400918/
https://www.ncbi.nlm.nih.gov/pubmed/22852011
http://dx.doi.org/10.5114/aoms.2012.29408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400918/
https://www.ncbi.nlm.nih.gov/pubmed/22852011
http://dx.doi.org/10.5114/aoms.2012.29408

Ejemplares similares